University College London (UCL) ECMC is committed to performing world-class clinical cancer research to develop new cancer therapies. It does this by conducting early phase clinical trials that are fully informed by modern molecular and imaging technologies. There is particular expertise and dedicated facilities for trials of antibody-targeted, radiation, photodynamic and vascular therapies, and biomedical informatics.
UCL/Great Ormond Street Hospital (GOSH) is also a paediatric centre. GOSH and the teenage cancer unit at UCLH comprise a unified Principal Treatment Centre (PTC) for those diagnosed with cancer aged 0-19 yrs in North London, treating over 300 new patients a year. Both units have an established infrastructure for running early phase trials linked to preclinical research at the Institute of Child Health and the UCL Cancer Institute, including dedicated Clinical Research Facilities (CRFs). They have recruited 18 patients to ITCC trials, 16 patients to a CRUK-supported phase I trial of dendritic cell vaccination in osteosarcoma and have strong clinical leadership and substantial grant funding (>£1.3 million) for in-house early phase trials in immunotherapy. There is a well-developed strategy to further enhance preclinical and early phase clinical trial research across the joint PTC. This includes the planned appointment in February 2011 of a new consultant with 50% of their time dedicated to experimental therapeutics. This post will increase the trial portfolio available to the paediatric and adolescent age groups, through interfacing with the adult ECMC and the CRF at UCH and working directly with Professor Hilary Calvert, UCL Partners Director of Drug Discovery and Development. Both GOSH and UCLH have facilities to accommodate patients and families who need to travel to London.
UCL Cancer InstitutePaul O'Gorman BuildingUniversity College London72 Huntley StreetLondon WC1E 6BT
Great Ormond Street Hospital for ChildrenGreat Ormond StreetLondonWC1N 3JH
Tim Meyer is Professor of Experimental Cancer Medicine at UCL and is Joint-Lead for the UCL ECMC. He is a Medical Oncologist with a clinical interest in Hepatocellular and Neuroendocrine for which he runs specialist clinics at the Royal Free Hospital. He also runs a research program at the UCL Cancer Institute which is mainly focussed on biomarker development, particularly in the field of circulating tumour cells.
Professor Meyer is also the Cancer Director for the NIHR/Wellcome UCH Clinical Research Facility which provides dedicated infrastructure for Cancer Drug Development and is central to the delivery of UCL’s ECMC program. At any one time, the unit has between 25-30 clinical trials evaluating new cancer therapies, and these are led by a team of highly experienced investigators. There is a close link between partner hospitals and the UCL Cancer Institute providing a seamless link between the laboratory bench and the clinic. Within the centre there is particular expertise in immunotherapy, cell-based therapy, biological therapy, imaging and cancer genomics.
Supported by imaging facilities, including SPECT CT, PET CT and MRI PET
Broad range of interests in small molecules, protein, physical and cellular therapies and mechanisms related to them.
•Brain and Nervous System
The Experimental Cancer Medicine Centre initiative is jointly funded by Cancer Research UK, the National Institute for Health Research in England and the Departments of Health for Scotland, Wales and Northern Ireland.